STOMP: Study of Tecovirimat for Human Monkeypox Virus
Study at a Glance
Estimated Time Commitment
8 weeks; Study medication for 14 days; Daily self-assessmentEligibility
Laboratory or presumptive Human MonkeyPox infection; Illness <14 days from study entry with at least one active (non-scabbed) lesion
Diagnosis Required
None—if enrolled as presumed, and swabs come back negative, will stop study drug and be followed for safetyDiseases Being Studied
Human Monkey Pox infectionClinicaltrials.gov identifier: NCT05534984